Trovagene Added to Russell Microcap Index

Russell Investments (Seattle, WA, USA) has added Trovagene (San Diego, CA, USA), a developer of transrenal molecular diagnostics, to the Russell Microcap Index. This was based on Russell Investments annual reconstitution of its family of US indexes, finalized after the close of the US markets on June 22, 2012.

Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

With US and European patent applications, Trovagene has issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

"We are pleased to be included as part of the Russell Microcap Index," said Antonius Schuh, PhD, CEO of Trovagene. "We believe that inclusion in the Index, along with our recent Nasdaq listing, will serve to broaden our investor base and increase our stock's liquidity as we continue to grow our business both domestically and globally."

Russell Investments (Russell) is a global asset manager and one of only a few firms that offer actively managed multiasset portfolios and services that include advice, investments, and implementation. Working with institutional investors, financial advisors, and individuals, Russell's core capabilities extend across capital markets insights, manager research, Indexes, portfolio implementation, and portfolio construction.

Related Links:
Russell Investments